IHSAN HAQ
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FINDLAY, OH NPI 1891789335
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology OH Regeneron Healthcare Solutions, Inc. All categories
General Payments — all program years on this page
$10,014.83
- Category: General Payments
- Program years: PY2018–2024
- Record count: 573
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,655.82 across 52 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,638.80 | 51 |
| Education | $17.02 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $291.87 | 4 |
| EISAI INC. | $184.05 | 3 |
| EMD Serono, Inc. | $140.81 | 2 |
| SOBI, INC | $137.95 | 2 |
| Acerta Pharma LLC | $98.26 | 4 |
| Janssen Biotech, Inc. | $85.01 | 3 |
| Merck Sharp & Dohme Corporation | $81.90 | 2 |
| Astellas Pharma US Inc | $81.30 | 4 |
| PUMA BIOTECHNOLOGY, INC. | $76.80 | 4 |
| Daiichi Sankyo Inc. | $73.87 | 3 |
| ABBVIE INC. | $61.85 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $53.89 | 2 |
| PFIZER INC. | $37.07 | 2 |
| Celgene Corporation | $28.94 | 2 |
| TerSera Therapeutics LLC | $22.83 | 1 |
| Ipsen Biopharmaceuticals, Inc | $21.50 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.93 | 1 |
| JAZZ PHARMACEUTICALS INC. | $20.88 | 1 |
| Blueprint Medicines Corporation | $20.35 | 1 |
| Genentech USA, Inc. | $18.23 | 1 |
| Gilead Sciences, Inc. | $18.02 | 1 |
| TAIHO ONCOLOGY, INC. | $17.76 | 1 |
| Karyopharm Therapeutics Inc. | $17.69 | 1 |
| BeiGene USA, Inc. | $15.25 | 1 |
| Kite Pharma, Inc. | $15.05 | 1 |
| E.R. Squibb & Sons, L.L.C. | $13.76 | 1 |
By program year
Records — PY2024 (52)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.